New drug duo aims to stop rare heart disease in its tracks

NCT ID NCT07608354

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This phase 2b trial tests whether adding ALXN2220 to eplontersen works better than eplontersen alone for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 326 participants will receive either the combination or eplontersen plus a placebo. The main goal is to see if the combo improves exercise capacity after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eplontersen (a drug) and ALXN2220 (a biologic)
What this could lead to: If successful, this combination could slow or stop heart damage from ATTR-CM, improving exercise ability and quality of life.
What could go wrong: This is a mid-stage trial with only 326 participants, so results may not apply to everyone. The added benefit of ALXN2220 over eplontersen alone is unproven, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)

Contacts and locations

Locations

Research Site

La Jolla, California, 92037, United States
Research Site

San Francisco, California, 94115, United States
Research Site

Stanford, California, 94305, United States
Research Site

Aurora, Colorado, 80045, United States
Research Site

Washington D.C., District of Columbia, 20010, United States
Research Site

Jacksonville, Florida, 32224, United States
Research Site

Miami, Florida, 33176, United States
Research Site

Weston, Florida, 33331, United States
Research Site

Chicago, Illinois, 60637, United States
Research Site

Boston, Massachusetts, 02115, United States
Research Site

Kansas City, Missouri, 64111, United States
Research Site

St Louis, Missouri, 63110, United States
Research Site

New York, New York, 10032, United States
Research Site

Chapel Hill, North Carolina, 27599, United States
Research Site

Durham, North Carolina, 27710, United States
Research Site

Cleveland, Ohio, 44195, United States
Research Site

Portland, Oregon, 97239, United States
Research Site

Danville, Pennsylvania, 17822, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Germantown, Tennessee, 38138, United States
Research Site

Dallas, Texas, 75390, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Salt Lake City, Utah, 84132, United States
Research Site

Falls Church, Virginia, 22042, United States
Research Site

Calgary, Alberta, T2N 4Z6, Canada
Research Site

Vancouver, British Columbia, V6Z 1Y6, Canada
Research Site

Halifax, Nova Scotia, B3H 3A7, Canada
Research Site

London, Ontario, N6A 5A5, Canada
Research Site

Toronto, Ontario, M5G 2C4, Canada
Research Site

Montreal, Quebec, H1T 1C8, Canada
Research Site

Beijing, 100034, China
Research Site

Beijing, 100730, China
Research Site

Changsha, 410012, China
Research Site

Chongqing, 400042, China
Research Site

Guangzhou, 510080, China
Research Site

Hangzhou, 310009, China
Research Site

Créteil, 94010, France
Research Site

Marseille, 13005, France
Research Site

Rennes, 35033, France
Research Site

Toulouse, 31059, France
Research Site

Berlin, 10117, Germany
Research Site

Cologne, 50937, Germany
Research Site

Essen, 45147, Germany
Research Site

Hamburg, 22767, Germany
Research Site

Heidelberg, 69120, Germany
Research Site

Homburg, 66421, Germany
Research Site

München, 81377, Germany
Research Site

Münster, 48149, Germany
Research Site

Bologna, 40138, Italy
Research Site

Florence, 50134, Italy
Research Site

Milan, 20138, Italy
Research Site

Padova, 35128, Italy
Research Site

Pavia, 27100, Italy
Research Site

Pisa, 56124, Italy
Research Site

Torino, 10154, Italy
Research Site

Torrette - Ancona, 60126, Italy
Research Site

Trieste, IT-34149, Italy
Research Site

Bunkyō City, 113-8431, Japan
Research Site

Kurume-shi, 830-0011, Japan
Research Site

Sapporo, 060-8543, Japan
Research Site

Shinjuku-ku, 160-8582, Japan
Research Site

Suita, 565-8565, Japan
Research Site

Barcelona, 08035, Spain
Research Site

Jaén, 23007, Spain
Research Site

L'Hospitalet de Llobregat, 08907, Spain
Research Site

Majadahonda, 28222, Spain
Research Site

Málaga, 29010, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Salamanca, 37007, Spain
Research Site

Valencia, 46010, Spain
Research Site

Gothenburg, 413 45, Sweden
Research Site

Lund, 22242, Sweden
Research Site

Stockholm, 171 64, Sweden
Research Site

Uppsala, 751 85, Sweden
Research Site

London, NW10 2PB, United Kingdom
Research Site

London, NW3 2QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.